Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Tingyu Yu, Jianxiang Chi & Li Wang. (2021) Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia. Hematology 26:1, pages 848-859.
Read now
Read now
Nicolas Duployez, Christophe Willekens, Alice Marceau-Renaut, Elise Boudry-Labis & Claude Preudhomme. (2015) Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. Expert Review of Hematology 8:1, pages 43-56.
Read now
Read now
Maurizio Miglino, Nicoletta Colombo, Gianmatteo Pica, Raffaella Grasso, Marino Clavio, Micaela Bergamaschi, Filippo Ballerini, Anna Ghiso, Chiara Ghiggi, Laura Mitscheunig, Germana Beltrami, Antonia Cagnetta, Luana Vignolo, Maria Vita Lucchetti, Sara Aquino, Ivana Pierri, Mario Sessarego, Angelo Michele Carella & Marco Gobbi. (2011) WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leukemia & Lymphoma 52:10, pages 1961-1969.
Read now
Read now
Jeffrey R. Andolina & Seth J. Corey. (2009) Are kinases factors in core binding factor leukemia?. Leukemia & Lymphoma 50:9, pages 1397-1398.
Read now
Read now
Articles from other publishers (24)
Jan Vydra, Emilio Cosimo, Petr Lesný, Richard Sebastian Wanless, John Anderson, Alan George Clark, Angela Scott, Emma Kate Nicholson & Michael Leek. (2023) A Phase I Trial of Allogeneic γδ T Lymphocytes From Haploidentical Donors in Patients With Refractory or Relapsed Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 23:5, pages e232-e239.
Crossref
Crossref
Shyam Srinivasan, Shathish Kumar, Kalasekhar Vijayasekharan & Amit Kumar Agrawal. (2022) Prevalence and Clinical Outcome of FMS-Like Tyrosine Kinase Mutations Among Patients With Core Binding Factor—Acute Myeloid Leukemia: Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma and Leukemia 22:4, pages e221-e232.
Crossref
Crossref
Akio Mori, Masahiro Onozawa, Daisuke Hidaka, Shota Yokoyama, Toru Miyajima, Emi Yokoyama, Reiki Ogasawara, Koh Izumiyama, Makoto Saito, Shinichi Fujisawa, Shuichi Ota, Yasutaka Kakinoki, Yutaka Tsutsumi, Satoshi Yamamoto, Takuto Miyagishima, Takahiro Nagashima, Hiroshi Iwasaki, Hajime Kobayashi, Yoshihito Haseyama, Mitsutoshi Kurosawa, Masanobu Morioka, Takanori Teshima & Takeshi Kondo. (2021) Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patients. International Journal of Hematology 115:2, pages 188-197.
Crossref
Crossref
Annalisa Talami, Francesca Bettelli, Valeria Pioli, Davide Giusti, Andrea Gilioli, Corrado Colasante, Laura Galassi, Rachele Giubbolini, Hillary Catellani, Francesca Donatelli, Rossana Maffei, Silvia Martinelli, Patrizia Barozzi, Leonardo Potenza, Roberto Marasca, Tommaso Trenti, Enrico Tagliafico, Patrizia Comoli, Mario Luppi & Fabio Forghieri. (2021) How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring. Biomedicines 9:8, pages 953.
Crossref
Crossref
Kateřina Kuželová, Adam Obr, Jana Marková & Zdenka Gašová. (2020) Integrin expression and adhesivity to fibronectin in primary acute myeloid leukemia cells: Impact of NPM1 and FLT3 mutations. European Journal of Haematology 105:5, pages 578-587.
Crossref
Crossref
Ahmed A. Alnagar, Asmaa A. Mahmoud, Mosaad M. EL Gammal, Naera Hamdy & Mohamed A. Samra. (2020) Outcome of Core Binding Factor Acute Myeloid Leukemia by Receptor Tyrosine Kinase Mutation. Clinical Lymphoma Myeloma and Leukemia 20:7, pages 459-467.
Crossref
Crossref
Robert Puckrin, Eshetu G. Atenafu, Jaime O. Claudio, Steven Chan, Vikas Gupta, Dawn Maze, Caroline McNamara, Tracy Murphy, Andre C. Shuh, Karen Yee, Hassan Sibai, Mark D. Minden, Cuihong Wei, Tracy Stockley, Suzanne Kamel-Reid & Aaron D. Schimmer. (2020) Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. Haematologica 106:1, pages 56-63.
Crossref
Crossref
Daniel A. Arber, Michael J. Borowitz, Melissa Cessna, Joan Etzell, Kathryn Foucar, Robert P. Hasserjian, J. Douglas Rizzo, Karl Theil, Sa A. Wang, Anthony T. Smith, R. Bryan Rumble, Nicole E. Thomas & James W. Vardiman. (2017) Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology. Archives of Pathology & Laboratory Medicine 141:10, pages 1342-1393.
Crossref
Crossref
Hossein Ayatollahi, Arezoo Shajiei, Mohammad Hadi Sadeghian, Maryam Sheikhi, Ehsan Yazdandoust, Masumeh Ghazanfarpour, Seyyede Fatemeh Shams & Sepideh Shakeri. (2017) Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review. Hematology/Oncology and Stem Cell Therapy 10:1, pages 1-7.
Crossref
Crossref
Graciele Burnatt, Marley Aparecida Licínio, Pâmela Cristina Gaspar, Arthur Schveitzer Ferreira, Manoela Lira Reis, Ana Carolina Rabello de Moraes, Thaís Cristine Marques Sincero & Maria Cláudia Santos-Silva. (2017) Analysis of the presence of FLT3 gene mutation and association with prognostic factors in adult and pediatric acute leukemia patients. Brazilian Journal of Pharmaceutical Sciences 53:2.
Crossref
Crossref
Wenlan Chen, Hui Xie, Hongxiang Wang, Li Chen, Yi Sun, Zhichao Chen & Qiubai Li. (2016) Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. PLOS ONE 11:1, pages e0146614.
Crossref
Crossref
Hana Hájková, Markus Hsi-Yang Fritz, Cedrik Haškovec, Jiří Schwarz, Cyril Šálek, Jana Marková, Zdeněk Krejčík, Michaela Dostálová Merkerová, Arnošt Kostečka, Martin Vostrý, Ota Fuchs, Kyra Michalová, Petr Cetkovský & Vladimír Beneš. (2014) CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia. Journal of Hematology & Oncology 7:1.
Crossref
Crossref
J-H Yoon, H-J Kim, J-W Kim, Y-W Jeon, S-H Shin, S-E Lee, B-S Cho, K-S Eom, Y-J Kim, S Lee, C-K Min, S-G Cho, J-W Lee, W-S Min & C-W Park. (2014) Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation. Bone Marrow Transplantation 49:12, pages 1466-1474.
Crossref
Crossref
Jana Brezinova, Iveta Sarova, Halka Buryova, Jana Markova, Sarka Ransdorfova, Silvia Izakova, Karla Kostylkova, Jacqueline Soukupova, Zuzana Zemanova & Kyra Michalova. (2014) Fusion of the additional sex combs like 1 and teashirt zinc finger homeobox 2 genes resulting from ider(20q) aberration in a patient with myelodysplastic syndrome. British Journal of Haematology 164:1, pages 153-155.
Crossref
Crossref
Jae-Ho Yoon, Hee-Je Kim, Seung-Hwan Shin, Seung-Ah Yahng, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park & Ji-Hyang Lim. (2013)
BAALC
and
WT1
expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML
. European Journal of Haematology 91:2, pages 112-121.
Crossref
Crossref
Sebastian Huss, Helen Künstlinger, Eva Wardelmann, Michaela A Kleine, Elke Binot, Sabine Merkelbach-Bruse, Thomas Rüdiger, Jens Mittler, Wolfgang Hartmann, Reinhard Büttner & Hans-Ulrich Schildhaus. (2013) A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del). Modern Pathology 26:7, pages 1004-1012.
Crossref
Crossref
Sang Hyuk Park, Hyun-Sook Chi, Young-Uk Cho, Seongsoo Jang & Chan-Jeoung Park. (2013) Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients. Leukemia Research 37:7, pages 784-789.
Crossref
Crossref
LUDOVICA RIERA, FILIPPO MARMONT, DANIELA TOPPINO, CHIARA FRAIRIA, FRANCESCA SISMONDI, ERNESTA AUDISIO, CRISTIANA DI BELLO, STEFANO D’ARDIA, PAOLA FRANCIA DI CELLE, EMANUELA MESSA, GIORGIO INGHIRAMI, UMBERTO VITOLO & ACHILLE PICH. (2013) Core binding factor acute myeloid leukaemia and c-KIT mutations. Oncology Reports 29:5, pages 1867-1872.
Crossref
Crossref
Eric JourdanNicolas BoisselSylvie ChevretEric DelabesseAline RennevillePascale CornilletOdile BlanchetJean-Michel CayuelaChristian RecherEmmanuel RaffouxJacques DelaunayArnaud PigneuxClaude-Eric BulaboisCéline BerthonCécile PautasNorbert VeyBruno LioureXavier ThomasIsabelle LuquetChristine TerréPhilippe Guardiola, Marie C. Béné, Claude PreudhommeNorbert Ifrah & Hervé Dombret. (2013) Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 121:12, pages 2213-2223.
Crossref
Crossref
Hana Hájková, Jana Marková, Cedrik Haškovec, Iveta Šárová, Ota Fuchs, Arnošt Kostečka, Petr Cetkovský, Kyra Michalová & Jiří Schwarz. (2012) Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation. Leukemia Research 36:9, pages 1128-1133.
Crossref
Crossref
James X. Gray, Lyle McMillen, Peter Mollee, Sanjoy Paul, Steven Lane, Robert Bird, Devinder Gill, Russell Saal & Paula Marlton. (2012) WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. Leukemia Research 36:4, pages 453-458.
Crossref
Crossref
Ling ZhaoJan J. MelenhorstLemlem AlemuMartha KirbyStacie AndersonMaggie KenchShelley Hoogstraten-MillerLauren Brinster, Yasuhiko KamikuboD. Gary Gilliland & P. Paul Liu. (2012) KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice. Blood 119:6, pages 1511-1521.
Crossref
Crossref
Jana Marková, Petra Michková, Kateřina Burčková, Jana Březinová, Kyra Michalová, Alena Dohnalová, Jacqueline Soukupová Maaloufová, Petr Soukup, Antonín Vítek, Petr Cetkovský & Jiří Schwarz. (2011)
Prognostic impact of
DNMT3A
mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia
. European Journal of Haematology 88:2, pages 128-135.
Crossref
Crossref
Ursula CreutzigMartin ZimmermannJean-Pierre BourquinMichael N. DworzakChristine von NeuhoffAnnette SanderAndré SchrauderAndrea Teigler-SchlegelJan Starý, Selim Corbacioglu & Dirk Reinhardt. (2011) Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood 118:20, pages 5409-5415.
Crossref
Crossref